Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The systematic review by Drs McGettigan and Henry1 provides a timely summary of the observational studies investigating the cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Nonetheless, as pointed out in the accompanying editorial by Dr Graham,2 data on the cardiovascular risk of celecoxib remain in conflict. Our case-control study,3 which was published too recently to be included in the meta-analysis, found a significantly increased risk of acute myocardial infarction associated with rofecoxib and celecoxib, as well as the newer etoricoxib. These findings are at odds with the conclusion of McGettigan and Henry that celecoxib in commonly used doses may not increase cardiovascular risk.
Andersohn F, Suissa S, Garbe E. Cyclooxygenase Inhibitors and Cardiovascular Risk. JAMA. 2007;297(6):586-588. doi:10.1001/jama.285.6.733